abs81.txt	breast	cancer	remains	a	leading	cause	of	death	for	women	throughout	the	world	recent	advances	in	medical	imaging	technologies	and	tumor	targeting	agentssignify	vast	potential	for	progress	toward	improved	management	of	this	globalproblem		phase-change	contrast	agents	(pccas)	are	dynamic	imaging	agents	withpractical	applications	in	both	the	research	and	clinical	settings		pccas	possesscharacteristics	that	allow	for	cellular	uptake	where	they	can	be	converted	fromliquid-phase	pccas	to	gaseous	microbubbles	via	ultrasound	energy		previously		wereported	successful	internalization	of	folate-targeted	pccas	in	mda-mb-231	breastcancer	cells	followed	by	ultrasound-mediated	activation	to	produce	internalizedmicrobubbles		this	study	examines	the	binding		internalization	and	activation	offolate-receptor	targeted	pccas	in	mda-mb-231	breast	cancer	cells	as	a	function	ofgaseous	core	compositions		incubation	time	and	ultrasound	exposure	period		invitro	results	indicate	that	internalization	and	ultrasound-mediated	activation	ofpccas	were	significantly	greater	using	a	50	50	mixture	ofdecafluorobutane	dodecafluoropentane	compared	with	other	core	compositions		50	50octafluoropropane	decafluorobutane	(p	<	0	0001)		decafluorobutane	(p	<	0	04)	anddodecafluoropentane	(p	<	0	0001)		furthermore		it	was	found	that	pccas	composedof	perfluorocarbons	with	higher	boiling	points	responded	with	greater	activationefficiency	when	exposed	to	12s	of	ultrasound	exposure	as	opposed	to	4s	ofultrasound	exposure		when	evaluating	different	incubation	times		it	was	foundthat	incubating	the	pccas	with	breast	cancer	cells	for	60min	did	not	producesignificantly	greater	internalization	and	activation	compared	with	incubation	for10	min		this	was	concluded	after	comparing	the	number	of	microbubbles	present	percell	before	ultrasound	versus	post-ultrasound		and	finding	a	ratio	ofintracellular	microbubbles	post-ultrasound/pre-ultrasound		3	46	versus	3	14	respectively		the	data	collected	in	this	study	helps	illustrate	furtheroptimization	of	folate-receptor	targeted	pccas	for	breast	cancer	targeting	andimaging	
